Author

Jill Thompson

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Immunodominant Antiviral T Cell Responses Outcompete Antitumor T Cell Responses to Reduce the Efficacy of Oncolytic Viroimmunotherapy.

The paradigm in the field of oncolytic virotherapy proposes that tumor cell killing by an oncolytic virus (OV) culminates in the priming of antitumor CD8+ T cells. However, this ignores the impact a highly immunodominant antiviral response against the OV has on the subdominant antitumor response, particularly regarding...

Benjamin L. Kendall, O. Liseth, T. Sangsuwannukul et al. · Cancer Research · 0 citations

Jul 2026

Engagement of the T cell receptor against an oncolytic virus generates a population of hypereffector CAR T cells with potent antitumor activity 2256915

Overall, CAR T cells that undergo endogenous anti-viral TCR priming and signaling adopt a unique phenotype that promotes their expansion and cytotoxic function.

Olivia Liseth, E. Appleton, Jill Thompson et al. · Journal of Immunology · 0 citations